Syntab Therapeutics has established a pipeline of different immuno-oncology drug candidates with bi- or multispecific properties of which the pilot candidate has already shown promising efficacy and toxicology data in-vivo. Furthermore, new binders against known and validated or even new molecular targets can be identified quickly and precisely.

Lead candidate Y9 targets Integrin alpha-3 to fight triple negative breast cancer

Syntab’s current pilot candidate Y9 is an Integrin alpha-binding ISEr against triple-negative breast cancer (TNBC) with convincing in-vitro and in-vivo studies. ISEr Y9 has demonstrated to fight tumors and prevent metastases. Further studies are in preparation. The bispecific molecule is broadly patented by Syntab.

TNBC is clinically defined as breast tumors lacking expression of estrogen receptor (ER) and progesterone receptor, with normal human epidermal growth factor receptor type 2 (HER2) gene copy number and expression. It accounts for approx. 15 to 20% of all breast cancers and is more prevalent in younger women. TNBC has an aggressive natural history, with an increased mortality rate during the first 5 years. Typically, there is a high risk of early recurrence. TNBC is treated with a combination of therapies such as surgery, radiation therapy, and chemotherapy. Some clinical trials of immunotherapy agents are in progress, but most of them are systemic approaches such as checkpoint inhibitors which demonstrate a tolerable safety profile in phase I.

The advantage of Syntab’s ISEr against TNBC is the promise of a change in the general approach being much more specific and precise than the other forms of treatment currently available and much higher in quality for the treatment of TNBC in the future.